Tocqueville Asset Management’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-2,000
| Closed | -$344K | – | 777 |
|
|
2021
Q3 | $344K | Hold |
2,000
| – | – | 0.01% | 605 |
|
|
2021
Q2 | $251K | Hold |
2,000
| – | – | ﹤0.01% | 672 |
|
|
2021
Q1 | $271K | Hold |
2,000
| – | – | ﹤0.01% | 660 |
|
|
2020
Q4 | $256K | Hold |
2,000
| – | – | ﹤0.01% | 646 |
|
|
2020
Q3 | $225K | Buy |
+2,000
| New | +$199K | ﹤0.01% | 610 |
|
|
2016
Q3 | – | Sell |
-19,750
| Closed | -$671K | – | 860 |
|
|
2016
Q2 | $671K | Buy |
19,750
+425
| +2% | +$13.8K | 0.01% | 573 |
|
|
2016
Q1 | $510K | Buy |
19,325
+8,000
| +71% | +$233K | 0.01% | 626 |
|
|
2015
Q4 | $552K | Hold |
11,325
| – | – | 0.01% | 641 |
|
|
2015
Q3 | $282K | Hold |
11,325
| – | – | ﹤0.01% | 821 |
|
|
2015
Q2 | $358K | Sell |
11,325
-250
| -2% | -$8.07K | ﹤0.01% | 800 |
|
|
2015
Q1 | $441K | Hold |
11,575
| – | – | 0.01% | 739 |
|
|
2014
Q4 | $451K | Buy |
11,575
+1,500
| +15% | +$52.3K | ﹤0.01% | 729 |
|
|
2014
Q3 | $305K | Sell |
10,075
-2,750
| -21% | -$77.5K | ﹤0.01% | 732 |
|
|
2014
Q2 | $436K | Sell |
12,825
-1,500
| -10% | -$50.2K | ﹤0.01% | 758 |
|
|
2014
Q1 | $494K | Buy |
14,325
+4,825
| +51% | +$218K | 0.01% | 579 |
|
|
2013
Q4 | $376K | Buy |
+9,500
| New | +$229K | 0.01% | 650 |
|
Tocqueville Asset Management's XLRN Position: Q4 2021 in Review
Tocqueville Asset Management sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 2,000 shares — an estimated $344K sold.
Tocqueville Asset Management first reported a position in XLRN in Q4 2013 and held it in 16 quarters. The position peaked at $671K in Q2 2016. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- Tocqueville Asset Management reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- Tocqueville Asset Management sold 2,000 Acceleron Pharma shares in Q4 2021, an estimated $344K.
- Tocqueville Asset Management first reported a position in Acceleron Pharma in Q4 2013 and held it in 16 quarters.
- Tocqueville Asset Management's Acceleron Pharma position peaked at $671K in Q2 2016.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on Tocqueville Asset Management's 13F filing for Q4 2021, filed 14 Feb 2022.